Timelike Systems

Respira Therapeutics Inc, based in Albuquerque, NM, is a pioneering company focused on developing next-generation inhalation products for cardiopulmonary diseases. With their advanced particle engineering and formulation approaches, combined with proprietary device technologies, Respira aims to enhance drug delivery to the lung periphery, specifically targeting patients with pulmonary arterial hypertension (PAH). Their lead drug-device product candidate, RT234-PAH, is a first-in-class inhaled therapy designed to provide acute relief from the most common symptoms of breathlessness and fatigue. With ongoing Phase 2 clinical trials for their pipeline candidate, Respira is at the forefront of respiratory treatment innovation. Their industry-leading experience and expertise are dedicated to developing therapeutic technology that may offer substantial new benefits for patients worldwide. Committed to patient well-being, Respira emphasizes the importance of genuine employment opportunities and warns against fraudulent job offers or financial commitments made by individuals falsely claiming to represent the company.Generated from the website

The Enhance Fund is a financial services firm based in Albuquerque, NM, specializing in investment management and wealth planning for individuals and businesses. With a focus on personalized strategies and long-term growth, The Enhance Fund aims to help clients achieve their financial goals through a comprehensive and tailored approach. Generated from their business information

Agilvax, located in Albuquerque, NM, is a cutting-edge biotechnology company specializing in the development of cancer immunotherapies and targeted vaccines for infectious diseases. Their innovative approaches, such as checkpoint inhibitors and CAR T-cell therapy, aim to empower the patient's immune system to fight cancer cells and boost immune responses against infectious diseases. With a focus on personalized medicine, Agilvax is at the forefront of advancing treatment paradigms and bringing new hope to patients worldwide. Agilvax's groundbreaking research and development in precision medicine have led to remarkable success in treating various cancers, including melanoma and non-small cell lung cancer, with drugs like pembrolizumab and nivolumab. Additionally, their targeted vaccines, exemplified by the mRNA vaccines for COVID-19, demonstrate their commitment to disease prevention and the advancement of effective and accessible treatments. As they continue to push the boundaries of medical research and technology, Agilvax is poised to redefine the approach to some of the most challenging diseases of our time, offering new hope to patients everywhere.Generated from the website